Tardive dyskinesia in schizophrenia

British Journal of Psychiatry

Volumn 203, Issue 1, 2013, Pages 6-7

  Liddle, Peter F ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

AGE DISTRIBUTION; AUDITORY HALLUCINATION; BASAL GANGLION; CAUDATE NUCLEUS; DISEASE PREDISPOSITION; DOPAMINERGIC TRANSMISSION; DRUG DOSE REDUCTION; FRONTAL CORTEX; GRAY MATTER; HUMAN; NEUROIMAGING; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PUTAMEN; REVIEW; SCHIZOPHRENIA; SUPERIOR TEMPORAL GYRUS; TARDIVE DYSKINESIA; THALAMUS;

BRAIN; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MOVEMENT DISORDERS; SCHIZOPHRENIA;

EID: 84879654440     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.123679     Document Type: Review

References (13)

1. Sarró S, Pomarol-Clotet E, Canales-Rodríguez EJ, Salvador R, Gomar JJ, Ortiz-Gil J, et al. Structural brain changes associated with tardive dyskinesia in schizophrenia. Br J Psychiatry 2013; 203: 51-7.
2. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982; 39: 452-61. (Pubitemid 12152814)
3. Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 1990; 3: 315-20. (Pubitemid 20383966)
4. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67: 231-9.
5. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999; 46: 56-72. (Pubitemid 29296818)
6. Palaniyappan L, Balain V, Radua J, Liddle PF. Structural correlates of auditory hallucinations in schizophrenia: a meta-analysis. Schizophr Res 2012; 46: 1249-56.
7. Palaniyappan L, Liddle PF. Does the salience network play a cardinal role in psychosis? An emerging hypothesis of insular dysfunction. J Psychiatry Neurosci 2012; 37: 17-27.
8. Hayashi-Takagi A, Sawa A. Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. Brain Res Bull 2010; 83: 140-6.
9. Liddle PF, Barnes TR, Speller J, Kibel D. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. Br J Psychiatry 1993; 163: 776-80. (Pubitemid 23352971)
10. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 1993; 50: 723-33. (Pubitemid 23263809)
11. Morgenstern H, Glazer WM, Niedzwiecki D, Nourjah P. The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies. Am J Public Health 1987; 77: 717-24. (Pubitemid 17084514)
12. Ebdrup BH, Nørbak H, Borgwardt S, Glenthøj B. Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr Med Chem 2013; 20: 438-47.
13. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68: 128-37.